ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Cadrenal Therapeutics Inc

Cadrenal Therapeutics Inc (CVKD)

4,13
-0,01
( -0,24% )
Aktualisiert: 19:30:03

Cadrenal Therapeutics Inc (CVKD) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
4,13
( -0,24% )
Gebot
4,00
Fragen
4,14
Volumen
15.777
4,05 Tagesbereich 4,26
3,90 52-Wochen-Bereich 15,99
Marktkapitalisierung
Handelsende
4,14
Handelsbeginn
4,11
Letzte Trade
100
@
4.13
Letzter Handelszeitpunkt
19:33:44
Finanzvolumen
US$ 64.921
VWAP
4,1149
Durchschnittliches Volumen (3 Mio.)
US$ 54.038
Ausgegebene Aktien
3.078.247
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-1,08
Gewinn pro Aktie (EPS)
-5,57
Erlöse (LTM)
-
Nettogewinn (LTM)
-11,89M

Über Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, ... Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Ponte Vedra, United States
Gegründet
2026
Cadrenal Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker CVKD. The last closing price for Cadrenal Therapeutics was US$4,14. Over the last year, Cadrenal Therapeutics shares have traded in a share price range of US$ 3,90 to US$ 15,99.

Cadrenal Therapeutics currently has 3.078.247 shares in issue. The market capitalisation of Cadrenal Therapeutics is US$12,71 million. Cadrenal Therapeutics has a price to earnings ratio (PE ratio) of -1.08.

CVKD Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.06-1.431980906924.194.633.9831814.20012885CS
4-1.3-23.941068145.435.88553.9674624.65601404CS
12-2.7701-40.14579498856.90017.273.9613175.27029438CS
26-7.83-65.468227424711.9612.53.9601926.66323088CS
52-10.78-72.300469483614.9115.993.9441928.49745397CS
1562.62173.5099337751.5122.90110.361238423.48810199CS
260-1.58-27.67075306485.7122.90110.361278983.43507864CS

CVKD - Frequently Asked Questions (FAQ)

What is the current Cadrenal Therapeutics Inc share price?
The current share price of Cadrenal Therapeutics Inc is US$ 4,13
How many Cadrenal Therapeutics Inc shares are in issue?
Cadrenal Therapeutics Inc has 3.078.247 shares in issue
What is the market cap of Cadrenal Therapeutics Inc?
The market capitalisation of Cadrenal Therapeutics Inc is USD 12,71M
What is the 1 year trading range for Cadrenal Therapeutics Inc share price?
Cadrenal Therapeutics Inc has traded in the range of US$ 3,90 to US$ 15,99 during the past year
What is the PE ratio of Cadrenal Therapeutics Inc?
The price to earnings ratio of Cadrenal Therapeutics Inc is -1,08
What is the registered address of Cadrenal Therapeutics Inc?
The registered address for Cadrenal Therapeutics Inc is 822 A1A North, Ponte Vedra, Florida, 32082
What is the Cadrenal Therapeutics Inc website address?
The website address for Cadrenal Therapeutics Inc is www.cadrenal.com
Which industry sector does Cadrenal Therapeutics Inc operate in?
Cadrenal Therapeutics Inc operates in the Biotechnology & Life Sciences sector

CVKD Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen